Contraception
Volume 53, Issue 1 , Pages 9-16 , January 1996

Interaction of oral contraceptive use with the effects of age, exercise habits and other cardiovascular risk modifiers on metabolic risk markers

  • Ian F. Godsland

      Affiliations

    • Corresponding Author InformationName and address for correspondence: I.F. Godsland, Ph.D., Wynn Institute for Metabolic Research, 21 Wellington Road, London, NW8 9SQ, UK. Tel: 01044-71-586-2266; Fax: 01044-71-586-3123

Received 11 September 1995 ,Revised 11 October 1995 ,Accepted 11 October 1995.

References 

  1. Oliver M. Oral contraceptives and myocardial infarction. Br Med J. 1970;2:210–213
  2. Radford D, Oliver M. Oral contraceptives and myocardial infarction. Br Med J. 1973;3:428–430
  3. Mann J, Vessey M, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J. 1975;2:241–245
  4. Mann J, Inman W. Oral contraceptives and death from myocardial infarction. Br Med J. 1975;2:245–248
  5. Mann J, Inman W, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. Br Med J. 1976;2:445–447
  6. Royal College of General Practitioners' Study . Mortality among oral contraceptive users. Lancet. 1977;ii:727–731
  7. Rosenberg L, Hennekens C, Rosner B, Belanger C, Rothman K, Speizer F. Oral contraceptive use in relation to non-fatal myocadial infarction. Am J Epidemiol. 1980;111:59–66
  8. Adam SA, Thorogood M, Mann JI. Oral contraception and myocardial infarction revisited: the effects of new preparations and prescribing patterns. Br J Obstet Gynaecol. 1981;88:838–845
  9. Royal College of General Practitioners' Oral Contraception Study . Further analyses of mortality in oral contraceptive users. Lancet. 1981;i:541–546
  10. Slone D, Shapiro S, Kaufman D, Rosenberg L, Miettinen O, Stolley P. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981;305:420–424
  11. Royal College of General Practitioners' Oral Contraception Study . Incidence of arterial disease among oral contraceptive users. J Roy Coll Gen Pract. 1983;33:75–82
  12. Rosenberg L, Kaufman D, Helmrich S, Miller D, Stolley P, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985;253:2965–2969
  13. Stampfer M, Willett W, Colditz G, Speizer F, Hennekens C. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med. 1988;319:1313–1317
  14. Vessey M, Villard-Mackintosh L, Yeates D. Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. Br Med J. 1989;299:1487–1491
  15. Rosenberg L, Palmer J, Lesko S, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol. 1990;131:1009–1016
  16. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with increased risk of myocardial infarction?—report of a case-control study. Br J Obstet Gynaecol. 1992;98:1245–1253
  17. Piper J, Kennedy D. Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol. 1987;16:215–221
  18. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. Obstet Gynecol. 1993;81:1034–1047
  19. Croft P, Hannaford P. Risk factors for acute myocardial infarction in women. Br Med J. 1989;298:674
  20. Hirvonen E, Idanpaan-Heikkila J. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol. 1990;163:281–284
  21. Crook D, Godsland I, Wynn V. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol. 1988;158:1612–1620
  22. Godsland IF, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol. 1994;170:1528–1536
  23. Godsland I, Crook D, Simpson R, Proudler T, Felton C, Lees B, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375–1381
  24. Godsland I, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74:64–70
  25. Metropolitan Life Insurance Company . New weight standards for men and women. Stat Bull Metropol Life Insur Co. 1959;40:1–4
  26. Rodriguez R. Influence of oestrogens and androgens on the production and prevention of diabetes. In:  Leibel B,  Wrenshall G editor. On the nature and treatment of diabetes. New York: Excerpta Medica; 1965;p. 288–307
  27. Costrini N, Kalkhoff R. Relative effects of pregnancy, estradiol and progesterone on plasma insulin and pancreatic islet insulin secretion. J Clin Invest. 1971;50:992–999
  28. Green I, ElSeifi S, Perrin D, Howell S. Cell replication in the islets of Langerhans of adult rats: effects of pregnancy, ovariectomy and treatment with steroid hormones. J Endocrinol. 1981;88:219–224
  29. Merians D, Haskell W, Vranizan K, Phelps J, Woods P, Superko R. Relationship of exercise, oral contraceptive use and body fat to concentrations of plasma lipids and lipoprotein cholesterol in young women. Am J Med. 1985;78:913–919
  30. Wynne T, Bassett-Frey M, Laudbach L, Glueck C. Effect of a controlled exercise program on serum lipoprotein levels in women on oral contraceptives. Metabolism. 1980;29:1267–1271
  31. Kruszon-Moran D, Burkman R, Kimball A, Bachorik P, Gold E. The interactions of alcohol consumption and oral contraceptive use on lipids and lipoproteins. Contraception. 1988;37:39–51
  32. Ernst N, Fisher M, Smith W, Gordon T, Rifkind B, Little J, et al. The association of plasma high density lipoprotein cholesterol with dietary intake and alcohol consumption: The Lipid Research Clinics Program Prevalence Study. Circulation. 1980;62(suppl iv):41–52

PII: 0010-7824(95)00260-X

Contraception
Volume 53, Issue 1 , Pages 9-16 , January 1996

Article Tools